This study investigates the use of cryoablation combined with a dual-function antibody for the treatment of locally advanced pancreatic cancer.
This study evaluates the effectiveness and safety of this approach as a second-line therapy option.
- Who can participate: Adults aged 18 and older with locally advanced pancreatic cancer who have experienced failure with first-line AG therapy may be eligible. Participants must have adequate organ function and an ECOG performance status of 0 to 2.
- Study details: Participants will undergo cryoablation combined with antibody therapy. An inactive substance that looks like the investigational medicine but does not contain any medicine may be used as a placebo.